{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=38",
    "query": {
      "intervention": "Single Dose Placebo",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 4629,
    "total_pages": 463,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T22:39:13.509Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06546709",
      "title": "DMID 23-0015; Lassa Fever CVD 1000",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lassa Fever"
      ],
      "interventions": [
        {
          "name": "LASSARAB+ aPHAD-SEat 700rU",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HDCV Comparator",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal Saline Placebo",
          "type": "OTHER"
        },
        {
          "name": "LASSARAB+ aPHAD-SEat 1400rU",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Wilbur Chen, MD, MS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 54,
      "start_date": "2025-01-13",
      "completion_date": "2026-05-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-11-16T22:39:13.509Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06546709"
    },
    {
      "nct_id": "NCT04464239",
      "title": "A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TS-142",
          "type": "DRUG"
        },
        {
          "name": "TS-142 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taisho Pharmaceutical R&D Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2020-09-14",
      "completion_date": "2021-01-21",
      "has_results": false,
      "last_update_posted_date": "2021-02-10",
      "last_synced_at": "2026-11-16T22:39:13.509Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04464239"
    },
    {
      "nct_id": "NCT01452607",
      "title": "Study to Evaluate the Safety and Pharmacokinetics of SPI-1005",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hearing Loss",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "SPI-1005",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sound Pharmaceuticals, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 32,
      "start_date": "2006-05",
      "completion_date": "2006-08",
      "has_results": false,
      "last_update_posted_date": "2016-06-29",
      "last_synced_at": "2026-11-16T22:39:13.509Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01452607"
    },
    {
      "nct_id": "NCT04302064",
      "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Eplontersen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "20 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2020-04-23",
      "completion_date": "2020-09-10",
      "has_results": false,
      "last_update_posted_date": "2022-03-31",
      "last_synced_at": "2026-11-16T22:39:13.509Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04302064"
    },
    {
      "nct_id": "NCT00927784",
      "title": "Effect of Intramyocardial Injection of Mesenchymal Precursor Cells on Heart Function in People Receiving an LVAD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Mesenchymal Precursor cells (RevascorTM)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cryoprotective media alone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2009-08",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-11-16T22:39:13.509Z",
      "location_count": 17,
      "location_summary": "San Diego, California • Washington D.C., District of Columbia • Oak Lawn, Illinois + 12 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00927784"
    },
    {
      "nct_id": "NCT01227512",
      "title": "Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyponatremia",
        "Dilutional Hyponatremia",
        "Inappropriate ADH Syndrome"
      ],
      "interventions": [
        {
          "name": "tolvaptan",
          "type": "DRUG"
        },
        {
          "name": "Fluid Restriction",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 124,
      "start_date": "2010-10",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-10-30",
      "last_synced_at": "2026-11-16T22:39:13.509Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Azusa, California + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Banning",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01227512"
    },
    {
      "nct_id": "NCT01706328",
      "title": "A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF/VI 100/25 Inhalation Powder NDPI",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS",
          "type": "DRUG"
        },
        {
          "name": "Placebo Inhalation Powder NDPI",
          "type": "DRUG"
        },
        {
          "name": "Placebo Inhalation Powder ACCUHALER/DISKUS",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol as needed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 828,
      "start_date": "2012-10-15",
      "completion_date": "2013-06-17",
      "has_results": true,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-11-16T22:39:13.509Z",
      "location_count": 16,
      "location_summary": "Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Woodbury",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01706328"
    },
    {
      "nct_id": "NCT03502707",
      "title": "A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV preF Protein 50 mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RSV preF Protein 150 mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ad26.RSV.preF 1*10^11 vp",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Selected Regimen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 669,
      "start_date": "2018-07-06",
      "completion_date": "2022-05-16",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-11-16T22:39:13.509Z",
      "location_count": 6,
      "location_summary": "Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03502707"
    },
    {
      "nct_id": "NCT04379492",
      "title": "A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "COVID19",
        "Sars-CoV2",
        "SARS-Cov-2"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-05-05",
      "completion_date": "2020-09-25",
      "has_results": false,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-11-16T22:39:13.509Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04379492"
    },
    {
      "nct_id": "NCT02926898",
      "title": "A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dravet Syndrome"
      ],
      "interventions": [
        {
          "name": "ZX008 (Fenfluramine Hydrochloride)",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 87,
      "start_date": "2017-01-27",
      "completion_date": "2018-06-05",
      "has_results": true,
      "last_update_posted_date": "2022-11-02",
      "last_synced_at": "2026-11-16T22:39:13.509Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02926898"
    }
  ]
}